Consolidated Balance Sheets - USD ($)	Dec. 31, 2017	Dec. 31, 2016
Current Assets
Cash and cash equivalents	$ 29,163,200	$ 7,076,651
Restricted cash	5,004,789	0
Marketable securities	25,916,681	0
Accounts receivable trade, net of allowance of $0 at December 31, 2017 and 2016, respectively	234,461	138,774
Prepaid and other current assets	790,514	1,900,493
Assets related to discontinued operations	0	15,533,043
Total current assets	61,109,645	24,648,961
Property, plant and equipment, net	256,905	705,438
Deferred tax assets	575,055	0
Other assets	1,434,077	1,582,209
Assets related to discontinued operations	0	26,577,834
Total assets	63,375,682	53,514,442
Current Liabilities
Accounts payable	1,343,089	2,226,580
Accrued liabilities	7,810,948	2,659,433
Long-term debt, current	0	3,126,457
Notes payable, current	159,180	563,777
Due to PCT	0	1,681,594
Liabilities related to discontinued operations	0	10,925,052
Total current liabilities	9,313,217	21,182,893
Notes payable	0	159,180
Long term debt	0	2,524,897
Other long-term liabilities	3,872,679	389,858
Liabilities related to discontinued operations	0	5,791,134
Total liabilities	13,185,896	30,047,962
Commitments and Contingencies
Redeemable Securities - Non-Controlling Interests	0	19,400,000
Stockholders' Equity
Preferred stock; authorized, 20,000,000 shares Series B convertible redeemable preferred stock liquidation value, 1 share of common stock, $.01 par value; 825,000 shares designated; issued and outstanding, 10,000 shares at December 31, 2017 and December 31, 2016, respectively	100	100
Common stock, $.001 par value, authorized 500,000,000 shares; issued and outstanding, 9,483,911 and 8,205,790 shares, at December 31, 2017 and December 31, 2016, respectively	9,484	8,206
Additional paid-in capital	433,044,209	410,372,049
Treasury stock, at cost; 11,080 shares at December 31, 2017 and December 31, 2016 respectively	(707,637)	(707,637)
Accumulated deficit	(381,810,109)	(404,788,809)
Accumulated other comprehensive loss	(27,978)	0
Total Caladrius Biosciences, Inc. stockholders' equity	50,508,069	4,883,909
Noncontrolling interests	(318,283)	(817,429)
Total equity	50,189,786	4,066,480
Liabilities and Equity, Total	$ 63,375,682	$ 53,514,442

Carrying value as of the balance sheet date of liabilities incurred (and for which invoices have typically been received) and payable to vendors for goods and services received that are used in an entity's business. Used to reflect the current portion of the liabilities (due within one year or within the normal operating cycle if longer).

Name:	us-gaap_AccountsPayableCurrent
Namespace Prefix:	us-gaap_
Data Type:	xbrli:monetaryItemType
Balance Type:	credit
Period Type:	instant

- Definition

Amount due from customers or clients, within one year of the balance sheet date (or the normal operating cycle, whichever is longer), for goods or services (including trade receivables) that have been delivered or sold in the normal course of business, reduced to the estimated net realizable fair value by an allowance established by the entity of the amount it deems uncertain of collection.